- Home
- ATNM vs MOB Comparison
ATNM vs MOB Comparison
Compare ATNM & MOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNM | MOB |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 75.1M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ATNM | MOB |
|---|---|---|
| Price | $1.42 | $7.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | 206.2K | ★ 327.2K |
| Earning Date | 11-14-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $90,000.00 | ★ $2,826,361.00 |
| Revenue This Year | N/A | $142.38 |
| Revenue Next Year | N/A | $99.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $1.31 |
| 52 Week High | $2.41 | $11.02 |
Technical Indicators
Market Signals| Indicator | ATNM | MOB |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 55.24 |
| Support Level | $1.33 | $5.88 |
| Resistance Level | $1.48 | $7.56 |
| Average True Range (ATR) | 0.11 | 0.89 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 58.90 | 78.49 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.